Erlotinib, a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is approved for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC) in the United States and Switzerland (Ling et al. 2006). Here, EGFR is linked to non-small cell lung carcinoma.